{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:46:42Z","timestamp":1793818002299,"version":"4.6.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.leukres.2022.106869","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T09:36:59Z","timestamp":1653212219000},"page":"106869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS\/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1"],"prefix":"10.1016","volume":"118","author":[{"given":"Davidson","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Entsar","family":"Eladl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Mario","family":"Capo-Chichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106869_bib1","first-page":"845","article-title":"AML with myelodysplasia-related changes: development, challenges, and treatment advances","volume":"11","author":"Koenig","year":"2020"},{"issue":"6","key":"10.1016\/j.leukres.2022.106869_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/ajcp\/aqaa107","article-title":"Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)","volume":"154","author":"Arber","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"issue":"18","key":"10.1016\/j.leukres.2022.106869_bib3","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2009-08-240457","article-title":"Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)","volume":"115","author":"Falini","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2022.106869_bib4","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1182\/blood-2010-09-307314","article-title":"The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status","volume":"116","author":"D\u00edaz-Bey\u00e1","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2022.106869_bib5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00277-014-2100-6","article-title":"Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1","volume":"93","author":"Rozman","year":"2014","journal-title":"Ann. Hematol."},{"issue":"20","key":"10.1016\/j.leukres.2022.106869_bib6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2022.106869_bib7","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1002\/cncr.27683","article-title":"Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia","volume":"118","author":"How","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106869_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.humpath.2020.08.003","article-title":"Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome","volume":"104","author":"Jiang","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.leukres.2022.106869_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HS9.0000000000000044","article-title":"Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: a single-center experience","volume":"2","author":"Alduaij","year":"2018","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.leukres.2022.106869_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5858\/arpa.2016-0547-RA","article-title":"Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies","volume":"141","author":"Thomas","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"9","key":"10.1016\/j.leukres.2022.106869_bib11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2022.106869_bib12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11899-020-00592-3","article-title":"NPM1 Biology in Myeloid Neoplasia","volume":"15","author":"Patel","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"11","key":"10.1016\/j.leukres.2022.106869_bib13","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/s41375-021-01222-4","article-title":"Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field","volume":"35","author":"Falini","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2022.106869_bib14","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2010.124","article-title":"Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML","volume":"24","author":"Dicker","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2022.106869_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/leu.2010.299","article-title":"Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms","volume":"25","author":"Schnittger","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2022.106869_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042334","article-title":"Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics","volume":"7","author":"Fernandez-Mercado","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.leukres.2022.106869_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/modpathol.2012.218","article-title":"Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia","volume":"26","author":"Courville","year":"2013","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106869_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hon.2656","article-title":"Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia","volume":"37","author":"Wang","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2022.106869_bib19","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.25769","article-title":"Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy","volume":"95","author":"Montalban-Bravo","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"29","key":"10.1016\/j.leukres.2022.106869_bib20","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:09Z","timestamp":1758934929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":20,"alternative-id":["S0145212622000959"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106869","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS\/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106869"}}